Researchers in Great Britain plan to test an experimental AIDS vaccine developed in the United States beginning this summer, and the tests will involve a few volunteers already infected with the disease, The New York Times reported Wednesday.

The vaccine, HGP-30, is made by Viral Technologies Inc. of Washington, D.C., from 30 amino acids. Viral Technologies officials told the Times that the British tests would be the first human AIDS vaccine trial in Europe. Early tests of at least four other AIDS vaccines are in progress in the United States and Zaire.

British health officials approved the experiments last week, Viral Technologies officials said.

The company applied for permission more than a year ago to test the HGP-30 vaccine among individuals in the United States who are not infected with the virus that causes acquired immune deficiency syndrome. Officials with the Food and Drug Administration to the newspaper that the application was under review and that they had asked for additional information.

Tests of the HGP-30 vaccine will involve 24 infected volunteers who will receive injections of varying doses.